Study TO Prevent Diabetes With Short-term Insulin Glargine Only

Summary

* Pre-diabetes is a significant risk factor for the development of type 2 diabetes, as well as macrovascular and microvascular complication. * Previous studies show that 50% or more loss in islet B-cell function even in Pre-diabetes phase. The early insulin therapy in pre-diabetes may be a strategy in preventing metabolic disorders and cardiovascular disease. * The objective of this study is to find if an initial insulin glargine intervention in pre-diabetes (IGT and /or IFG) could be a strategy in preventing type 2 Diabetes. * Pre-diabetes subjects will receive a insulin glargine therapy with a dosage adjusted to get FBG ≤ 5.3mmol / L as the goal. Insulin glargine treatment will be maintained for three months thereafter to find if it can prevent diabetes.

Timeline

Start

2011-01

Primary completion

2013-10

Completion

2013-12

Drugs

Indications